New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2012
07:42 EDTAHS, CPHD, CLDX, IART, BIOS, USPH, PBTH, ARNA, DXCM, INSMOppenheimer to host a conference
23rd Annual Healthcare Conference is being held in New York on December 12-13 with webcasted presentations to begin on December 12 at 7:45 am; not all company presentations may be webcasted. Webcast Link
Check below for free stories on AHS;DXCM;ARNA;PBTH;USPH;BIOS;IART;CLDX;CPHD;INSM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
17:39 EDTCPHDCepheid sees Q2 revenue $113M-$115M, consensus $110.68M.
Subscribe for More Information
16:10 EDTCPHDCepheid sees FY14 non-GAAP EPS 19c-24c, may not compare with consensus (24c)
Sees FY14 revenue in the range of $446M-$461M. Sees FY14 net loss in a range from $(0.43) to $(0.38) per share. Expected non-GAAP net income excludes approximately $33M related to stock compensation expense, approximately $9M related to the amortization of debt discount and debt issuance costs, and approximately $3M related to the amortization of acquired intangibles.
16:07 EDTCPHDCepheid reports Q1 non-GAAP EPS (1c), may not compare with consensus (17c)
Subscribe for More Information
15:29 EDTCPHDNotable companies reporting after market close
Notable companies reporting before tomorrow's market open, with earnings consensus, include athenahealth (ATHN), consensus 17c; Allison Transmission (ALSN), consensus 31c; Investors Bancorp (ISBC), consensus 24c; Cepheid (CPHD), consensus (17c); Advanced Micro Devices (AMD), consensus 0c; Associated Banc-Corp (ASBC), consensus 25c; Hub Group (HUBG), consensus 36c; Capital Bank (CBF), consensus 24c; Select Comfort (SCSS), consensus 32c; Acacia Research (ACTG), consensus 4c.
April 16, 2014
14:02 EDTCLDXCelldex Phase 1 study of CDX-1401 demonstrates robust antibody response
Subscribe for More Information
April 15, 2014
09:23 EDTIARTBarclays medical supplies/devices analysts hold analyst/industry conference call
Subscribe for More Information
08:19 EDTCLDXLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
April 10, 2014
16:58 EDTINSMJames Flynn reports 7.75% passive stake in Insmed
10:00 EDTDXCMOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:50 EDTDXCMDexCom upgraded at Sterne Agee
As noted earlier, Sterne Agee upgraded DexCom to Buy from Neutral. The firm expects the company to generate strong annual revenue growth, and believes that use of its G4 Platinum product will become more widespread after the FDA approved it for people ages 2-17. Target $50.
07:03 EDTCPHDCepheid announces European release of Xpert Norovirus
Cepheid announced the release of Xpert Norovirus, a qualitative in vitro diagnostic test for rapid identification and differentiation of Noroviruses genogroup I and genogroup II, to be marketed as a CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices. The test runs on Cepheid's GeneXpert System.
05:54 EDTDXCMDexCom upgraded to Buy from Neutral at Sterne Agee
Price target is $50.
April 9, 2014
06:48 EDTCPHDCepheid upgraded to Outperform from Market Perform at JMP Securities
Subscribe for More Information
06:00 EDTCPHDCepheid upgraded to Outperform from Market Perform at JMP Securities
Subscribe for More Information
April 8, 2014
11:03 EDTARNAPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
09:09 EDTBIOSOn The Fly: Pre-market Movers
HIGHER: BioScrip (BIOS), up 6.7% after stock was named as a stock pick and a potential takeover target by Oscar Schafer while speaking on CNBC... Nokia (NOK), up 5% after deal to sell substantially all of its Devices & Services business to Microsoft (MSFT) receives regulatory approval in China... (CTRP), up 4.6% after Bloomberg said, citing sources, that the company is in talks with Baidu-controlled (BIDU) Qunar (QUNR) about a partnership or a potential merger... Plug Power (PLUG), up 4.6% after CEO discusses plan to expand fuel cells to trucks in interview... FireEye (FEYE), up 2.5% following upgrade at Wedbush... Twitter (TWTR), up 2% following initiation of coverage with a Buy rating at at Janney Capital... Nike (NKE), up 1.75% after upgraded at Stifel. LOWER: Gigamon (GIMO), down 23% after lowering revenue outlook, shares downgraded at Pacific Crest... LivePerson (LPSN), down 3% after announcing resignation of EVP, Worldside Sales, shares downgraded at Benchmark... Cisco (CSCO), down 0.5% following downgrade to Hold from Buy at Wunderlich.
09:00 EDTBIOSBioScrip rises 6.6%
Subscribe for More Information
07:40 EDTBIOSBioScrip, InterXion, RealD mentioned as stock picks by Oscar Schafer
Pharmacy and home health services provider BioScrip (BIOS) was named as a stock pick and a potential takeover target by Oscar Schafer, managing partner of O.S.S. Capital Management and chairman of Rivulet Capital, while speaking on CNBC. Schafer also mentioned data center service provider InterXion (INXN) and 3D technology licensor RealD (RLD) as stock picks during his appearance on the network.
April 7, 2014
16:02 EDTCLDXCelldex says CDX-014 to enter clinical development
Celldex Therapeutics reported results of preclinical studies evaluating the anti-tumor activity of CDX-014 against a variety of cell lines. Based on the results, CDX-014 will enter clinical development. CDX-014 is an antibody drug conjugate that targets the protein TIM-1. "The data presented today confirm that CDX-014 effectively targets the tumor marker TIM-1 in vitro and elicits significant anti-tumor activity in key models. We are currently completing manufacturing and IND-enabling studies and anticipate that CDX-014 will enter Phase 1 clinical studies in renal cell carcinoma and potentially other TIM-1 expressing tumors in 2015," said Tibor Keler, senior VP and Chief Scientific Officer of Celldex.
07:24 EDTINSMInsmed data likely supports accelerated approval in NTM, says Piper Jaffray
Piper Jaffray believes Insmed's data for Arikayce in nontuberculous mycobacteria is likely to support accelerated approval, especially if the relapse rate is modest. Piper says recent data for Arikayce has caused "considerable controversy" and it reiterates an Overweight rating on shares of Insmed.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use